Clinical Trial Update: A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study of CC-99712, a BCMA-directed antibody-drug conjugate, in relapsed and refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-99712

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED